Transgenic C57BIV6N mice containing a X shuttle vector carrying a lacl target and an a-lacZ reporter gene have been used to study the modulating effect of phorone, a glutathione-depleting agent, on the mutagenic activity of aflatoxin I*! (AFT*!) in vivo. Animals were treated with AFB, (8 nag/kg) for four consecutive days and the animals sacrificed 21 days after the last treatment Treatment with AFB] alone did not result in a significant increase in mutation frequency in the liver and kidney. When the animals were treated with phorone 4 h prior to treatment with AFB[ a significant increase in mutation frequency was observed in the liver (4-fold) and kidney (1.5-fold). Phorone treatment did not increase the AFB,-induced mutation frequency in the lung and intestine. DNA sequence analyses of 30 independent clones isolated from the liver of AFB,-treated animals showed that G:C-»T:A transversion (60%) was the predominant mutational event Mutations within the lacl gene could not be detected in seven of 30 mutants. The mutations were randomly distributed throughout the coding sequences of the lacl gene and no hotspots for the mutations were observed. However, codons 86 and 928 appeared to be major sites for mutation. The study shows that the transgenic mouse in vivo mutagenesis model can be used to study the influence of effect-modifying compounds on the mutagenic activity of known carcinogens.
Introduction
Aflatoxin B, (AFB|), produced by Aspergillus flavus under hot and humid conditions, is a potent liver carcinogen in experimental animals and a suspected human carcinogen (IARC, 1993) . AFB, is activated by the cytochrome P450 mixed function oxidase system to the carcinogenic intermediate AFB,-8,9-epoxide, a process mediated by at least five different liver P450s. Genetic variability in the expression of these and other P450 enzymes may result in substantial inter-species and intra-strain differences in susceptibility to the carcinogenic action of AFB, (Eaton and Gallagher, 1994) . The carcinogenic intermediate AFB r 8,9-epoxide, reacts with DNA to form the covalently bound 8,9-dihydro-8-(A^7-guanyl)-9-hydroxyaflatoxin B, (AFB.-Gua) adduct. The level of AFB,-Gua adducts in rat liver was >50-fold higher in the F344 rat than in CD1 mice (Croy and Wogan, 1973) . A positive association between AFB|-DNA adduct levels and tumor incidence has been established, e.g. trout and rat (Bechtel, 1989) .
The AFB r 8,9-epoxide will react with reduced glutathione (GSH) in a process mediated by glutathione S-transferase (GST) (Neal and Green, 1983) to form detoxified products.
Mice are thought to be protected from the carcinogenic activity of AFBj by a GST isoenzyme with high activity towards the biologically active form of AFB, (Ramsdell and Eaton, 1990 ). Depletion of the cellular level of GSH potentiates the organ toxicity induced by many xenobiotics. Treatment of mice with the GSH-depleting agent phorone has been shown to increase the level of covalently bound AFB, in the liver and in a number of extra-hepatic tissues (Larsson and Tjavle, 1992) . In species susceptible to the carcinogenic action of AFB ,, e.g. rat, treatment of the animals with compounds that induce GST activity will render these animals less sensitive to the carcinogenic activity of AFB, (Maxuitenko et ai, 1993) .
Specific mutations in genes involved in the carcinogenic process have been seen in tumours induced by AFB) in experimental animals, e.g. activation of the c-Ki-ras oncogene. The predominant mutation in AFB,-induced rat liver tumours was G:C->A:T base transitions, with a low frequency of G:C->T:A transversions (Soman and Wogan, 1993) . In human hepatocellular carcinomas a high frequency of G:C->T:A transversions was reported in cases living in areas with high levels of contamination of the food with AFB, (Hsu et ai, 1991) and the mutation frequency and pattern were different from that in Western countries, with a low level of exposure to AFB,.
Development of transgenic mouse strains expressing the bacterial lacl target and a-lacZ reporter genes has made it possible to measure mutant frequencies and mutational spectra in different organs following exposure to a mutagenic substance. A number of different mutagenic agents have been tested in this system (Mirsalis et ai, 1993) .
The objective of this study was to investigate the mutagenic activity of AFB] in mouse liver and extra-hepatic tissues and to study the effect of a GSH-depleting agent on the mutation frequency.
Material and methods
Chemicals AFB, and phorone were purchased from Sigma Chemical Co. (St Louis, MO) and 5-bromo-4-chloro-3-indoyl-f}-D-galactopyranoside (X-gal), biological reagents and enzymes from Stratagene (La Jolla, CA).
Animals
Six-week-old male lacl transgenic C57BL/6N (BigBlue™) mice were purchased from Stratagene Cloning Systems (Cambridge, UK). The animals were housed in plastic cages with oven-dried beech tree wood-chip bedding. Food (Altromin no. 1324; Chr.Petersen, Ringsted, Denmark) and water were supplied ad libitum. Mice were acclimatized for at least 2 weeks prior to treatment and were kept under a 12 h light/dark cycle. Permission to conduct the experiment was obtained from the national animal experimentation committee.
Experimental design
To study the mutagenic activity of AFB| in mice animals were treated i.g. with a non-toxic dose of AFB, [4 or 8 mg/kg body wt dissolved in dimethylsulphoxide (DMSOVcom oil (1:1)] for 4 consecutive days. The control animals received DMSO/com oil only. In addition, phosphate-buffered saline (PBS)-treated animals were included as a control for baseline mutation frequency in the liver and kidney. Twenty one days after the last treatment the mice were killed by asphyxiation and the organs removed aseptically and HAutnip, E.C.B Jergensen and OJensen frozen immediately in liquid nitrogen. The intestines were carefully washed in PBS, pH 7.4, and the epithelial layers removed by scraping. The tissues were stored in liquid nitrogen until isolation of the DNA. A minimum of five animals was used in each treatment group. In order to deplete the intracellular GSH level the animals were treated i.g. with phorone (250 mg/kg) dissolved in corn oil 4 h prior to treatment with AFB|.
Mutant frequency determination
Genomic DNA was isolated from the organs according to the Stratagene Big Blue™ Transgenic Mouse Mutagenesis Assay System instruction manual (Stratagene, La Jolla, CA). After ethanol precipitation the DNA was resuspended in a suitable amount (1CKMO0 u.1) of Tris-EDTA buffer (10 mM Tris-HC1, pH 7.6, 1 mM EDTA) and allowed to stand at room temperature for at least 24 h before storage at 4"C.
The /ac/-containing \ shuttle vector was recovered from bulk genomic DNA with a X phage packaging extract (Transpack; Stratagene) according to the manufacturer's instruction. The DNA extracts from the individual mice organs were analysed separately. Packaged phage was pre-absorbed to Escherichia coli SCS-8 cells for 20-30 min at 37°C, mixed with prewarmed (48°C) NZY top agarose containing 1.2 mg/ml X-Gal (dissolved in NJJdimethylformamide) and poured into square plates (25 X 25 cm) containing NZY agar. Two plates with 2 ml SCS-8 cells mixed with 50 ]i.\ cell/phage solution were used as counting plates. Plates were incubated overnight at 37°C. lacr mutants express the enzyme galactosidase and the substrate Xgal will be degraded, thus mutant plaques can be identified by their blue colour. The total number of colourless lacl + plaques was estimated from the counting plates and the blue lad~ plaques were counted from the experimental plates, which each contained -15 000 plaques. More than 280 000 plaques were analysed per organ for each animal. The lad mutant frequency was calculated by dividing the number of mutant plaques by the total number of plaques analysed.
DNA sequence analysis
The lad gene was sequenced from lad~ mutants isolated from the liver of AFB| + phorone-treated animals. The mutant colonies were selected on the basis of colour intensity, using plaques classified as at least CM1 on the scale CM1-CM3 given by Stratagene. The colonies were individually picked with a Pasteur pipette, transferred to SM buffer (500 |il) and stored at room temperature for 2 h. The SM buffer was diluted with DMSO to a final concentration of 10% and stored at -70°C until analysis.
Before sequencing all mutants were replated at low density on Petri dishes. Plaques were picked and boiled in TE (25 u.1) for 2 min followed by RNase treatment (I ug) for 1 h at room temperature. After centrifugation 15 \l\ supernatant was used as template in sequencing reactions according to the protocol for the Big Blue Cyclist™ Exo" pfu DNA sequencing kit. The lad gene was sequenced using the Big Blue™ sequencing primers until a mutation was identified. These primers cover the entire coding region of the lad gene.
Statistical analysis
Student's /-test was used to evaluate the mutation frequency in the AFB r treated animals compared with the controls.
Results
AFB| is a potent mutagen in many experimental in vitro systems. Transgenic mice expressing a X shuttle vector carrying 6.5 ± 0.6 11.9 ± 1.1 17.5 ± 3.2 3.2 11.0 ± 1.9
11.7 ± 3.5
13.6 ± 3.1
Animals were treated with phorone (250 mg/kg) 4 h prior to treatment with AFB, (8 mg/kg).
The results are expressed as no. mutants/10 5 p.f.u. and represent the mean ± SD of three to six animals.
a lad target gene have been used to study AFB,-induced mutations in vivo. AFB r induced lact~ mutation frequency was studied in the liver, kidney and large intestine of mice treated for 4 consecutive days with either 4 or 8 mg AFB]/kg body wt, giving a total dose of 16 or 32 mg/kg, with an expression time of 21 days after the last treatment. In preliminary assays treatment with AFB, at the lowest doses did not significantly increase the mutation frequency in liver, lung and intestinal DNA compared with that in DMSO/corn oil-treated control animals. The mutation frequency in the DMSO-treated animals was in the range 8.8-18.5 per 10 5 p.f.u. and was higher than in PBS-treated animals. At the high dose level of AFB, the mutation frequency was significantly increased in both the liver and kidney (P < 0.05), but not in the large intestine, compared with the phorone-treated group (Table I) .
High levels of cellular GSH and GST activity in the liver is assumed to protect mice against the carcinogenic action of AFB i. Treatment of mice with phorone 4 h prior to treatment with AFB! resulted in a significant increase in mutation frequency in liver (P < 0.05) and kidney DNA (P < 0.05) and a slight, but non-significant, increase in the mutation frequency in the large intestine. Phorone treatment alone did not have any effect on the mutation frequency.
Thirty independent mutants from phorone + AFB|-treated mouse livers were sequenced to determine the specific mutations in the lad gene. Using the BigBlue primers mutations in the reading frame could be detected in 23/30 mutants. One mutation was observed outside the reading frame at position 1206. Most mutations were localized in the DNA binding domain of the lad gene. Single base substitutions accounted for 67% (20/30 mutants) and G:C->T: A transversion (60%) was the predominant mutation. Two insertion and one deletion mutations were also observed (Table II) . The AFB r induced mutations were not site specific, but occurred frequently in GC-rich domains. However, three mutations were detected at G86 (CCGTT) and G928 (AGCG) respectively.
Discussion
Mice are generally considered one of the least sensitive species to AFBi-induced liver carcinogenesis. However, when treated with repeated doses of AFB, at 2 mg/kg an increase in hepatocellular carcinomas and adenomas was observed in female transgenic mice of C57BL/6N background, which overexpress the hepatitis B large virus envelope (Sell et al., 1991) . The liver is the primary site of pathological and biochemical effects in the rat induced by AFB,, whereas the kidney is the most sensitive tissue in the mouse (Akao et al., 1971) . Feeding aflatoxin-contaminated com to CD1 male mice for 4 weeks induced a significantly increased level of micronuclei and sister chromatid exchanges (SCE) in circulating peripheral lymphocytes (Marques-Marques et al, 1993) , but did not induce micronuclei and SCE in bone marrow of NMRI mice treated with a high dose of AFB, (Madle et al., 1986) . lact~ transgenic mice have been used to study the in vivo genotoxic action in different organs of a number of different known mutagens (Mirsalis et al. 1993; Morrison and Ashby, 1994) . Using the Big Blue mouse system we found an increased level of mutations in the kidney after AFB, treatment alone, whereas no increase was observed in the liver. This is in agreement with the observations by Croy and Wogan (1973) , who found that the AFBi-DNA adduct level in AFB r treated mice was 3-fold higher in the kidney than in the liver. This higher level of damage in the kidney may also be related to the pathobiological effects observed in the kidney after treatment with AFB, (Akao et al, 1971) .
Glutathione dramatically reduces binding of the activated form of AFB | to DNA and proteins both in vivo and in vitro. Depletion of GSH in rats with ethanol increased the covalent binding of AFB, to liver DNA and potentiated the hepatotoxic effect of AFB, (Wang et al, 1990) . Furthermore, depletion of GSH by L-buthionine sulfoximine enhanced the number and area of preneoplastic foci induced by AFB, in young male rats (Gopolan et al., 1993) . Similar observations have been made for other groups of chemical carcinogens and a 5-fold increase in PhlP-DNA adduct level was seen in the liver of rats treated with buthionine sulfoximime (Kaderlik et al., 1994) . In the present study, treatment of mice with the GSHdepleting agent phorone resulted in an increase in AFB r induced mutation frequency in the kidney and liver, but the increase in the kidney was not as dramatic as in the liver. Phorone treatment had only a slight effect on mutation frequency in the large intestine. Colonic tissues from experimental animals have previously been shown to express mixed function oxidase activity and to metabolize AFB, to the AFB|-epoxide that reacts with DNA (Autrup et al., 1980) . This suggests that detoxification of the active metabolite by glutathione conjugation may not be as important a pathway in extrahepatic tissues as in the liver or that a GST isoenzyme highly specific for AFB, (Quinn et al., 1990) is not expressed in the kidney and large intestine. It has previously been shown that phorone reduces the level of GSH in the liver and extra-hepatic tissues without influencing the activities of the mixed function oxidase system and glutathione transferases (Younes et al, 1986) .
The major adduct formed between AFB, and DNA both in vitro and in vivo in different species and organs has been identified as AFBi-A^-Gua and this adduct is supposed to play an important role in both AFB! mutagenesis and carcinogenesis. The distribution of mutations within a gene is influenced by several variables, including DNA damage, DNA repair and mutational bypass during replication, each of which may be influenced by DNA specificity. G:C-»T:A transversion was the predominant mutation after in vitro modification of shuttle vector systems with metabolically activated AFB], e.g. the lad gene of the uvrB strain of E.coli (Foster et al, 1983) and the pS189 supF gene (Courtemanache and Anderson, 1994) . This type of mutation is similar to that in the p53 cancer suppressor gene in liver cancer cases from areas with high exposure to AFB and to that in human hepatocytes treated with AFB, (Cerutti et al, 1994) . It has been proposed that the G:C-»T:A transversion mutation was generated by depurination of the guanine residue, and preferential insertion of adenine opposite the apurinic sites has been postulated to underlie the mutational specificity (Foster et al, 1983) . Apurinic sites are also formed by 8-hydroxydeoxyguanosine and an elevated level of this type of adduct has been observed in rat liver after a single treatment with AFB| (Shen et al, 1995) .
In agreement with the in vitro observations, we found that the predominant lad mutation in mouse liver DNA of animals treated with phorone prior to treatment with AFB, was G:C-»T:A transversions. In the M13-borne lacZ target G:C->T:A transversions were produced to the same extent as G:C-»A:T transitions (Sambamurti et al, 1988) , but this transitional mutation was not observed in the Big Blue™ mouse system. Only two G:C->C:G transversions were detected in die liver from AFB|-treated mice. This type of mutation has been observed in the pS 189-borne supF target gene replicated in human cells (Levy et al, 1992) .
Mutations in the coding regions of the lad gene could not be detected in six of 30 blue plaques using the Big Blue™ sequencing primers and mutations in regions affecting the stability of the gene product or increased production of auxiliary proteins may be responsible for the galactosidase activity.
No mutational hotspot was observed in the lad gene following AFB | treatment in vivo. However, three mutations each occurred at location 86 (CCGTT) and location 928 (TCGCT). These mutations are located in the DNA binding domain and dimer formation domain respectively. Most of the previously reported mutations following treatment of the lacl mouse with chemical mutagens occurred in these domains (Mirsalis et al, 1993) . AFB, has been found to react with DNA at preferential sites in some in vitro mutagenesis systems, e.g. a mutational hotspot in exon 3 of the human HPRT gene in a GGGGGG sequence (Cariello et al, 1994) and at position 2 in S.typhimurium hisG46 (Koch et al, 1994) .
The present results indicate that transgenic lacl mice can be used to study the in vivo mutational spectrum in target tissues for potential carcinogenic activity, but more interestingly, the influence of compounds that modify the carcinogenic outcome can be investigated at the level of mutations.
